Bydureon Approved for Use With Basal Insulin for Uncontrolled T2D

Bydureon pen
Bydureon pen
The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.

AstraZeneca announced that the Food and Drug Administration (FDA) has approved Bydureon® (exenatide extended-release for injectable suspension) as an add-on to basal insulin in adults with type 2 diabetes who have inadequate glycemic control.

Bydureon is currently indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. The expanded approval was supported by data from the DURATION-7 study which compared Bydureon vs placebo as add-on therapy to insulin glargine, with or without metformin, in adults with type 2 diabetes. Patients with a mean baseline HbA1c of 8.5% who received Bydureon experienced a 0.9% mean HbA1c reduction vs 0.2% in the placebo arm (difference 0.6%; <.001). 

Also, more patients in the Bydureon arm achieved HbA1c <7.0% compared with those in the placebo arm (32.5% vs 7.0%). No new safety signals were observed in the study; the rate of overall hypoglycemia was similar between the treatment arms (29.7% vs 29.0%). Nausea, diarrhea, headache, vomiting, constipation, injection-site pruritus, injection-site nodule, and dyspepsia were the most commonly reported adverse events. 

Exenatide is a glucagon-like peptide-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. It is available as a 2mg strength powder for subcutaneous injection after reconstitution. 

For more information call (800) 237-8898 or visit

Related Articles

This article originally appeared on MPR